BACKGROUND AND AIMS: The aim of this study was to characterize circulating tumor cells (CTCs) during neoadjuvant chemotherapy (NACT) in early and locally advanced breast cancer (LABC) patients. Using ultrasound, tumor volume measurement was compared with the presence and the molecular nature of CTCs over multiple time intervals corresponding to treatment periods. METHODS: A total of 20 patients diagnosed with breast cancer (BC) of different histotypes were monitored during the NACT period and in the follow-up period (~5 years). Peripheral blood for CTCs (n = 115) was taken prior to NACT, after two to three chemotherapy cycles, after the completion of NACT (before surgery) and at some time points during adjuvant therapy. CTCs were enriched using a size-based filtration method (MetaCell®) capturing viable cells, which enabled vital fluorescence microscopy. A set of tumor-associated (TA) genes and chemoresistance-associated (CA) genes was analyzed by qPCR in the enriched CTC fractions. RESULTS: The analysis of tumor volume reduction after administration of anthracyclines (AC) and taxanes (TAX) during NACT showed that AC therapy was responsive in 60% (12/20) of tumors, whereas TAX therapy was responsive in 30% (6/20; n.s.). After NACT, CTCs were still present in 70.5% (12/17) of patients (responders versus non-responders, 61.5% versus 100%; not significant).In triple-negative BC (TNBC) patients (n = 8), tumor volume reduction was observed in 75% cases. CTCs were significantly reduced in 42.9% of all HER2-negative BC patients. In HER2+ tumors, CTC reduction was reported in 16.6% only. Relapses were also more prevalent in the HER2-positive patient group (28.5 versus 66.6%).During NACT, the presence of CTCs (three tests for each patient) identified patients with relapses and indicated significantly shorter progression-free survival (PFS) rates (p = 0.03). Differentiation between progressive disease and non-progressive disease was obtained when the occurrence of excessive expression for CA genes in CTCs was compared (p = 0.024). Absence of tumor volume reduction was also significantly indicative for progressive disease (p = 0.0224).Disseminated CTCs in HER2-negative tumors expressed HER2 in 29% of samples collected during the overall follow-up period (16/55), and in 32% of samples during the follow-up of NACT (10/31). The change accounted for 78.5% of HER2-negative patients (11/14) in total, and 63.6% of the conversion cases occurred during NACT (7/11). For the remaining four patients (36.3%), conversion to HER2+ CTCs occurred later during adjuvant therapy. We believe there is the possibility of preventing further progression by identifying less responsive tumors during NACT using CTC monitoring, which could also be used effectively during adjuvant therapy.

Department and Clinic of Thoracic Surgery Faculty of Medicine Wroclaw Medical University Wrocław Poland

Department of Oncology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Radiotherapy and Oncology Clinic Laboratory of Personalized Medicine University Hospital Kralovske Vinohrady Prague Czech Republic

Radiotherapy and Oncology Clinic Laboratory of Personalized Medicine University Hospital Kralovske Vinohrady Srobarova 50 Prague 100 34 Czech Republic

Zobrazit více v PubMed

Rastogi P, Anderson SJ, Bear HD, et al.. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778–785. PubMed

Van der Hage JA, van de Velde CJ, Julien JP, et al.. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19: 4224–4237. PubMed

Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188–194. PubMed

Colleoni M, Bonetti M, Coates AS, et al.. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: the International Breast Cancer Study Group. J Clin Oncol 2000; 18: 584–590. PubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717. PubMed

Bear HD, Anderson S, Smith RE, et al.. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J CIin Oncol 2006; 24: 2019–2027. PubMed

Sorlie T, Tibshirani R, Parker J, et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418–8423. PubMed PMC

Cortazar P, Zhang L, Untch M, et al.. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164–172. PubMed

Von Minckwitz G, Untch M, Blohmer JU, et al.. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796–1804. PubMed

Symmans WF, Peintinger F, Hatzis C, et al.. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414–4422. PubMed

Von Minckwitz G, Schmitt WD, Loibl S, et al.. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013; 19: 4521–4531. PubMed

Cristofanilli M, Budd G, Ellis M, et al.. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781–791. PubMed

Zhang L, Riethdorf S, Wu G, et al.. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012; 18: 5701–5710. PubMed

Bidard FC, Peeters D, Fehm T, et al.. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of European studies. Lancet Oncol 2014; 15: 406–414. PubMed

Smerage JB, Barlow WE, Hortobagyi GN, et al.. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014; 32: 3483–3489. PubMed PMC

Liu Y, Liu Q, Wang T, et al.. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer 2013; 13: 202. PubMed PMC

Bidard FC, Fehm T, Ignatiadis M, et al.. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013; 32: 179–188. PubMed PMC

Gkountela S, Szczerba B, Donato C, et al.. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open 2016; 1: 1–9. PubMed PMC

Aceto N, Bardia A, Miyamoto DT, et al.. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158: 1110–1122. PubMed PMC

Paoletti C, Li Y, Muñiz MC, et al.. Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res 2015; 21: 2771–2779. PubMed PMC

Vafaei S, Roudi R, Madjd Z, et al.. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell Int 2020; 20: 1–15. PubMed PMC

Wallwiener M, Hartkopf AD, Riethdorf S, et al.. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer 2015; 15: 403. PubMed PMC

Mego M, Giordano A, De Giorgi U, et al.. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res 2015; 17: 2. PubMed PMC

Yusa A, Toneri M, Masuda T, et al.. Development of a new rapid isolation device for circulating tumor cells (CTCs) using palladium filter and its application for genetic analysis. PLoS One 2014; 9: e88821. PubMed PMC

Peeters DJ, van Dam PJ, Van den Eynden GG, et al.. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer 2014; 110: 375–383. PubMed PMC

Lee SK, Kim GS, Wu Y, et al.. Nanowire substrate-based laser scanning cytometry for quantification of circulating tumor cells. Nano Lett 2012; 12: 2697–2704. PubMed PMC

Zhang JL, Yao Q, Chen Y, Wang JH, et al.. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer. Genet Mol Res 2015; 14: 2099–2103. PubMed

Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol 2020; 10: 1–15. PubMed PMC

Cavdarli S, Groux-Degroote S, Delannoy P. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules 2019; 9: 311. PubMed PMC

Orsi G, Barbolini M, Ficarra G, et al.. GD2 expression in breast cancer. Oncotarget 2017; 8: 31592–31600. PubMed PMC

Mansoori M, Roudi R, Abbasi A, et al.. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol 2019; 109: 25–35. PubMed

Yardley DA, Melisko ME, Forero A, et al.. Expression patterns of gpNMB in breast cancer (BC): retrospective evaluation of tumor tissue from the phase II EMERGE study. J Clin Oncol 2015; 33: 129–129.

Cocco S, Piezzo M, Calabrese A, et al.. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives. Int J Mol Sci 2020; 21: 1–34. PubMed PMC

Yardley DA, Weaver R, Melisko ME, et al.. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol 2015; 33: 1609–1619. PubMed

Bardia A, Mayer IA, Vahdat LT, et al.. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 2019; 380: 741–751. PubMed

Bredemeier M, Edimiris P, Tewes M, et al.. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget2016; 7: 41677–41690. PubMed PMC

Lasa A, Garcia A, Alonso C, et al.. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One 2013; 8: e74079. PubMed PMC

Molloy TJ, Devriese LA, Helgason HH, et al.. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer 2011; 104: 1913–1919. PubMed PMC

Bitisik O, Saip P, Saglam S, et al.. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res 2009; 9: 97–106. PubMed

Fehm T, Hoffmann O, Aktas B, et al.. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11: R59. PubMed PMC

Banys M, Krawczyk N, Becker S, et al.. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 2012; 132: 121–129. PubMed

Fehm T, Krawczyk N, Solomayer EF, et al.. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10: R76. PubMed PMC

Aktas B, Müller V, Tewes M, et al.. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122: 356–360. PubMed

Krawczyk N, Banys M, Neubauer H, et al.. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 2009; 29: 4019–4024. PubMed

Klezl P, Pospisilova E, Kolostova K, et al.. Detection of circulating tumor cells in renal cell carcinoma: disease stage correlation and molecular characterization. Clin Med 2020; 9: 1–10. PubMed PMC

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–408. PubMed

Pierga JY, Bidard FC, Mathiot C, et al.. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14: 7004–7010. PubMed

Bidard FC, Belin L, Delagoge S, et al.. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the remagus02 study. Int J Breast Cancer 2013; 2013: 130470. PubMed PMC

Riethdorf S, Müller V, Zhang L, et al.. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634–2645. PubMed

Xenidis N, Perraki M, Apostolaki S, et al.. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer 2013; 108: 549–556. PubMed PMC

Franken B, de Groot MR, Mastboom WJ, et al.. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 2012; 14: R133. PubMed PMC

Pachmann K, Camara O, Kavallaris A, et al.. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26: 1208–1215. PubMed

Xenidis N, Perraki M, Kafousi M, et al.. Predictive and prognostic value of peripheral blood cytokeratin 19 mRNA positive cells detected by real time polymerase chain reaction in node negative breast cancer patients. J Clin Oncol 2006; 24: 3756–3762. PubMed

Lavrov AV1, Zubtsova ZhI, Zubtsov DA, et al.. Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy. Bull Exp Biol Med 2014; 157: 159–161. PubMed

Serrano MJ, Rovira PS, Martínez-Zubiaurre I, et al.. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med 2012; 4: 43–48. PubMed PMC

Camara O, Rengsberger M, Egbe A, et al.. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 2007; 18: 1484–1492. PubMed

Pierga JY, Bidard FC, Autret A, et al.. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol 2017; 28: 103–109. PubMed

Sabatier R, Pierga JY, Curé H, et al.. Circulating tumor cells and bevacizumab pharmacokinetics during neoadjuvant treatment combining chemotherapy and bevacizumab for early breast cancer: ancillary analysis of the AVASTEM trial. Cancers (Basel) 2021; 13: 1–13. PubMed PMC

Rack BK, Schindlbeck C, Andergassen U, et al.. Use of CTCs in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: the SUCCESS trial. J Clin Oncol 2010; 28: abstract 1003.

Goodman ChR, Speers CW. The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions. Int J Radiat Oncol Biol Phys 2021; 109: 44–59. PubMed

Riethdorf S, Müller V, Loibl S, et al.. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res 2017; 23: 5384–5393. PubMed

Bidard FC, Michiels S, Riethdorf S, et al.. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst 2018; 110: 560–567. PubMed

Von Minckwitz G, Rezai M, Loibl S, et al.. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III 12. GeparQuattro study. J Clin Oncol 2010; 28: 2015–2023. PubMed

Von Minckwitz G, Eidtmann H, Rezai M, et al.. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299–309. PubMed

Miller K, O’Neill AM, Dang CT, et al.. Bevacizumab (BV) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 2014; 32(Suppl. 15): abstract 500.

Baselga J, Bradbury I, Eidtmann H, et al.. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633–640. PubMed PMC

Gianni L, Pienkowski T, Im YH, et al.. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25–32. PubMed

Schneeweiss A, Chia S, Hickish T, et al.. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278–2284. PubMed

Sikov WM, Berry DA, Perou CM, et al.. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33: 13–21. PubMed PMC

Von Minckwitz G, Schneeweiss A, Loibl S, et al.. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15: 747–756. PubMed

Von Minckwitz G, Kummel S, Vogel P, et al.. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552–562. PubMed

Müller V, Stahmann N, Riethdorf S, et al.. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005; 11: 3678–3685. PubMed

Rack B, Schindlbeck Ch, Jückstock J, et al.. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106: 1–11. PubMed PMC

van Dalum G, van der Stam GJ, Tibbe AGJ, et al.. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol 2015; 46: 407–413. PubMed

Trapp E, Janni W, Schindlbeck Ch, et al.. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst 2019; 111: 380–387. PubMed

Sparano J, O’Neill A, Alpaugh K, et al.. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018; 4: 1700–1706. PubMed PMC

Bidard FC, de Rycke Y, Asselain B, et al.. CirCe T-DM1 phase II trial: assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1. Cancer Res 2013; 73(Suppl. 24): abstract OT1-1-10.

Fehm T, Müller V, Aktas B, et al.. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010; 124: 403–412. PubMed

SABCS.Org [homepage on the Internet]. The San Antonio Breast Cancer Symposium, December. http://www.sabcs.org (2013, accessed 21 February 2014).

Bidard F, Baffert S, Hajage D, et al.. Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial. Cancer Res 2012; 72(Suppl. 24): abstract OT3-4-06.

Paoletti C, Regan MM, Liu MC, et al.. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial. Cancer Res 2017; 77(4_Suppl): Abstr. P1-01-01.

Yu M, Bardia A, Aceto N, et al.. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216–220. PubMed PMC